Altis Labs

1. Requirement for abundant independent user reviews prior to procurement

   • Public user-review presence for this vendor is limited. Organizations that require broad third-party review validation may prefer alternatives with more visible adoption signals.

2. Need for explicit, publicly documented compliance attestations

   • If procurement requires public SOC 2 or ISO 27001 artifacts, the public materials for this vendor (as found in this review) may be insufficient. Security documentation may be available under NDA.

3. Trials that do not rely on CT imaging or are outside the model’s validated scope

   • If validated model scope is limited to certain cancers, protocols, or imaging modalities, additional validation work may be required for other contexts.

4. Requirement for an immediately regulator-accepted endpoint

   • The pathway from AI-derived imaging biomarkers to regulatory-grade endpoints typically requires substantial validation and stakeholder engagement. Organizations seeking a single turnkey, regulator-accepted solution without investment in validation and change management should evaluate alternatives.

• Model scope constraints: the specific cancer types, disease stages, imaging modalities, and required protocol parameters that the models support.
• External validation: performance when applied outside the training distribution.
• Explainability and auditability: whether outputs provide sufficient detail for internal QA and regulatory documentation.
• API / export formats: whether outputs integrate easily with sponsor analytics pipelines and data warehouses.

• G2: No clear, reputable G2 listing with user reviews for Altis Labs’ Nota or IPRO was located in the accessible results. A search result for a different "Altus"/"Altis" entity appeared, indicating a brand collision risk.
• TrustRadius: No credible TrustRadius product page with end-user reviews for Altis Labs was found in the accessible results.
• Gartner Peer Insights: A Gartner Peer Insights listing was identified for a different company (Altis Consulting Data and Analytics Services), which is not related to Altis Labs and therefore not usable as evidence about this product.

Implication: Altis Labs appears underrepresented on mainstream SaaS review platforms, which is common for niche, enterprise life-sciences tools sold via direct deals.

Because direct product reviews are scarce, sentiment is inferred primarily from:

• Presence of named collaborations or announcements (for example, a major pharmaceutical company; a digital-twin coalition including several pharma participants).
• Continued public announcements across multiple years (Nota launch press in the early 2020s; receipt of early-stage funding; partnership announcements across multiple years).

These signals suggest some level of market engagement, but they do not demonstrate routine operational performance, support quality, or return-on-investment in day-to-day use without further evidence.

1. CENGN "Innovation Highlight" PDF describes Nota and reports that in a lung cancer cohort, Altis’ algorithms showed a reported substantial improvement in outcome predictions over the stated comparator.

   • Critical evaluation: The claim appears in partner highlight materials rather than a peer-reviewed publication. Methodological details (dataset size, baseline comparator, metric definitions, and external validation) were not visible in the captured snippet. Organizations should request the underlying evaluation report, methodology, and raw results for independent assessment.

2. Colby News profile includes statements that Altis’ analysis could detect survival benefit earlier than traditional approaches (for example, a statement referencing detection several months earlier).

   • Critical evaluation: This is a narrative feature article; details on study design, whether the analysis was retrospective or prospective, and statistical validation are not fully presented in the accessible excerpt.

• Digital twins / computational control arm initiative (Aug 23, 2023): Altis announced participation in a coalition positioned to implement digital twins in trials, with Nota cited as an enabling platform.

  • Critical evaluation: Digital twins receive significant attention in the industry. Organizations should request concrete evidence that computational control arms were accepted by sponsors or regulators for decision-making, and clarify the specific conditions and constraints under which they were used.

• Collaboration with Johnson & Johnson Innovative Medicine (June 23, 2025): The company announced a collaboration to evaluate novel outcome measures.

  • Critical evaluation: Partnership announcements indicate vendor engagement with major organizations but do not disclose whether the solution materially changed trial decisions or timelines.

Altis Labs is a computational imaging vendor that develops AI models trained on longitudinal medical imaging (primarily CT) linked with clinical context and outcomes to generate predictive outputs for clinical research and drug development. The company states that its models are intended to enable biopharma sponsors and clinical researchers to extract richer, more reproducible signals from imaging than traditional radiology endpoints (for example, size-based measurements), with the stated objective of informing trial decision-making (for example, stratification and go/no-go decisions) and potentially reducing timelines and costs.

Official positioning includes the phrases "predictive imaging insights" and states an aim to "predict drug efficacy to accelerate clinical R&D." These are vendor positioning statements; independent validation and regulatory acceptability should be confirmed during diligence.

• Primary buyers/users:
  • Biopharma clinical development and translational science teams running Phase 1–3 oncology trials (and potentially broader therapeutic areas where CT imaging is central).
  • Academic medical centers and clinician scientists conducting imaging research.
• Positioning: An imaging-AI biomarker and prognostication layer that integrates with clinical trial imaging workflows; positioned to support evidence generation and sensitivity to treatment effects for clinical development decisions.